5-(1-trityl-1H-imidazol-4-yl)pentanal | 188698-46-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 5-(1-trityl-1H-imidazol-4-yl)pentanal
• 英文别名: ω-[1-(triphenylmethyl)-1H-imidazol-4-yl]-pentanal；5-[1-(triphenylmethyl)imidazol-4-yl]pentanal；5-(1-tritylimidazol-4-yl)pentanal
• CAS: 188698-46-6
• 化学式: C₂₇H₂₆N₂O
• 分子量: 394.516
• InChiKey: YZXZEIFSZRUXLF-UHFFFAOYSA-N

物化性质

• 沸点：
  557.6±38.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  30
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  34.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(1-trityl-1H-imidazol-4-yl)pentanal 在 盐酸 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.17h， 生成 N-ethyl-5-(1H-imidazol-5-yl)pentan-1-amine
  参考文献：
  名称：

  A Chemical Switch for the Modulation of the Functional Activity of Higher Homologues of Histamine on the Human Histamine H₃ Receptor:  Effect of Various Substitutions at the Primary Amino Function

  摘要：

  In ail effort to establish the structural requirements for agonism, neutral antagonism, and inverse agonism at the human histamine H-3 receptor (H3R) we have prepared a series of higher homologues of histamine in which the terminal nitrogen of the side chain has been either mono- or disubstituted with several aliphatic, alicyclic, and aromatic moieties or incorporated in cyclic systems. The novel ligands have been pharmacologically investigated in vitro for their affinities on the human H3R and H4R subtypes by radioligand displacement experiments and for their intrinsic H3R activities via a CRE-mediated P-galactosidase reporter gene assay. Subtle changes of the substitution pattern at the side chain nitrogen alter enormously the pharmacological activity of the ligands, resulting in a series of compounds with a wide spectrum of pharmacological activities. Among the several neutral H3R antagonists identified within this series, compounds 2b and 2h display an H3R affinity in the low nanomolar concentration range (pK(i) values of 8.1 and 8.4, respectively). A very potent and selective H3R agonist (1l, pEC(50) 8.9, alpha = 0.94) and a very potent, though not highly selective, H3R inverse agonist (2k, pIC(50) = 8-9, alpha -0.97) have been identified as well.

  DOI：

  10.1021/jm0504353
• 作为产物：
  描述：

  6-羟基己酸甲酯 在 lithium aluminium tetrahydride 、 草酰氯 、 氰化钠 、 氨 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 52.75h， 生成 5-(1-trityl-1H-imidazol-4-yl)pentanal
  参考文献：
  名称：

  A Chemical Switch for the Modulation of the Functional Activity of Higher Homologues of Histamine on the Human Histamine H₃ Receptor:  Effect of Various Substitutions at the Primary Amino Function

  摘要：

  In ail effort to establish the structural requirements for agonism, neutral antagonism, and inverse agonism at the human histamine H-3 receptor (H3R) we have prepared a series of higher homologues of histamine in which the terminal nitrogen of the side chain has been either mono- or disubstituted with several aliphatic, alicyclic, and aromatic moieties or incorporated in cyclic systems. The novel ligands have been pharmacologically investigated in vitro for their affinities on the human H3R and H4R subtypes by radioligand displacement experiments and for their intrinsic H3R activities via a CRE-mediated P-galactosidase reporter gene assay. Subtle changes of the substitution pattern at the side chain nitrogen alter enormously the pharmacological activity of the ligands, resulting in a series of compounds with a wide spectrum of pharmacological activities. Among the several neutral H3R antagonists identified within this series, compounds 2b and 2h display an H3R affinity in the low nanomolar concentration range (pK(i) values of 8.1 and 8.4, respectively). A very potent and selective H3R agonist (1l, pEC(50) 8.9, alpha = 0.94) and a very potent, though not highly selective, H3R inverse agonist (2k, pIC(50) = 8-9, alpha -0.97) have been identified as well.

  DOI：

  10.1021/jm0504353

文献信息

• Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
  申请人：——

  公开号：US20020086859A1

  公开（公告）日：2002-07-04

  The present invention discloses novel substituted imidazole compounds which have dual histamine-H 1 and H 3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.

  本发明揭示了新颖的取代咪唑化合物，其具有双重组胺-H1和H3受体拮抗活性，以及制备这些化合物的方法。在另一实施方式中，本发明揭示了包含这些咪唑类化合物的药物组合物，以及使用它们治疗过敏、炎症和中枢神经系统相关疾病等方法。
• ω-(Imidazol-4-yl)alkane-1-sulfonamides: a new series of potent histamine H3 receptor antagonists
  作者：Matthew J. Tozer、Ildiko M. Buck、Tracey Cooke、S.Barret Kalindjian、Michael J. Pether、Katherine I.M. Steel

  DOI：10.1016/s0968-0896(01)00295-4

  日期：2002.2

  omega-(1H-imidazol-4-yl)alkane-1-sulfonamides were prepared and found to be potent histamine H-3 receptor antagonists. High receptor affinity and a low difference in the data between the bioassays were achieved with 5-(1H-imidazol-4-yl)pentane-1-sulfonic acid 4-chlorobenzylamide (16). Good in vitro profiles were also obtained for 2-hydroxysulfonamide and vinylsulfonamide analogues. This complements and completes the existing set of imidazole-based sulfonamides and sulfamides. (C) 2001 Elsevier Science Ltd. All rights reserved.
• N-(IMIDAZOLYLALKYL)SUBSTITUTED CYCLIC AMINES AS HISTAMINE-H 3? AGONISTS OR ANTAGONISTS
  申请人：SCHERING CORPORATION

  公开号：EP1121354A1

  公开（公告）日：2001-08-08
• N-(IMIDAZOLYLALKYL)SUBSTITUTED CYCLIC AMINES AS HISTAMINE-H 3 AGONISTS OR ANTAGONISTS
  申请人：SCHERING CORPORATION

  公开号：EP1121354B1

  公开（公告）日：2004-12-08
• SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS
  申请人：Schering Corporation

  公开号：EP1318993B1

  公开（公告）日：2008-08-20